Lancet Gastroenterology & Hepatology

Article	Citations
Research in Brief	1422
EASL Congress 2024	494
GORD: pain, PPIs, and preciseness	457
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	417
Research in Brief	416
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	391
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	371
Lucky: Learning to Live Again	307
Viral hepatitis: time for action	292
The changing prevalence of functional constipation: why words matter	286
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	267
Treatment withdrawal in Crohn's disease: slowly becoming clearer	252
Immune checkpoint inhibitors in colorectal cancer: dream and reality	246
Trends in alcohol-specific deaths in the UK and industry responses	232
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	206
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	205
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	203
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	202
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	200
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	199
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	197
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	196
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	196
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	192
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	173

Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	166
Global multi-stakeholder endorsement of the MAFLD definition	158
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	156
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	148
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	147
ACG 2024	140
Rare cause of dysphagia in a young woman	138
Water and sanitation for all	136
Bringing organ preservation closer for selected patients with rectal cancer	130
The potential of ctDNA in locoregional therapies for colorectal cancer	128
Addressing the rise of early-onset colorectal cancer	125
Management of portal vein thrombosis in cirrhosis	122
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	120
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	119
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	117
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	111
Availability of point-of-care HBV tests in resource-limited settings	110
Local and systemic therapy in liver cancer: the quest for synergy	110
All roads lead to the gut–brain microbiome network	110
Research in Brief	105
Idiopathic gastroparesis consensus misses the patient's voice	105
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	104
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	102
Long-term VEDOKIDS results: implications for practice and research	100
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	99
Resmetirom for NASH: balancing promise and prudence	98
Has the time come for a systematic top-down approach in Crohn's disease?	97
Uptick of food allergies in recent years—real or epiphenomenon?	97
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study	94
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	94
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	94
Sex and gender in inflammatory bowel disease outcomes and research	93
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	92
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	91
Practicalities accessing precision medicine in biliary tract cancer	91
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	91
Britta Siegmund: answering the big questions in IBD	90
Management of malignant bowel obstruction – Authors' reply	90
Research in Brief	89
Robotic versus laparoscopic surgery for middle and low rectal cancer	88
The Year My Life Went Down the Toilet	86
Lifting the minority tax in gastroenterology and hepatology	85
Managing inflammatory bowel disease: what to do when the best is unaffordable?	80
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	79
Hypovolaemic phlebotomy for hepatic resection	78
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	77
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	77
Research in Brief	76
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	76
Dangerous Medicine	76

Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	75
CEND-1: a game changer for pancreatic cancer chemotherapy?	74
An unusual complication after a variceal glue injection	73
Another arrow in the NASH quiver?	71
The growth of faecal microbiota transplantation in the UK: time for a registry?	71
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	70
Shitbag: the story of a diagnosis	69
18th Congress of the European Crohn's and Colitis Organisation	69
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	68
Primary biliary cholangitis and the narrowing gap towards optimal disease control	67
A women-focused matrix mentorship programme in gastroenterology	67
Urgent action needed to achieve viral hepatitis elimination	66
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	66
Diversity in clinical trials: an opportunity and imperative for community engagement	65
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	64
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	64
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	63
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	62
Correction to Lancet Gastroenterol Hepatol 2021; 6: 781	61
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	61
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	60
COP27 Climate Change Conference: urgent action needed for Africa and the world	60
The world is failing on hunger	60
Research in Brief	60
Compensation advised for UK victims of contaminated blood scandal	60
Primary intestinal lymphangiectasia	59
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	59
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	57
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	56
Research in brief	56
Management of portal vein thrombosis in cirrhosis – Authors' reply	55
Bowel cancer prevention: are we missing an opportunity?	55
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	54
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	53
Alcohol and health: time for Europe to sober up	52
Combining systemic and local therapies for hepatocellular carcinoma	52
Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination	52
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	52
The problem of antimicrobial resistance in chronic liver disease	50
Laparoscopic versus open pancreatoduodenectomy for pancreatic or peri-ampullary tumours	50
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	49
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	49
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	49
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	48
Increasing burden of colorectal cancer in China	47
The intestinal barrier: a pivotal role in health, inflammation, and cancer	47
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	47
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	47
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	47
Research in Brief	46
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	46
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	46
Urgent action needed to eliminate viral hepatitis by 2030	46
DEI in gastroenterology and hepatology	45
Research in Brief	45
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	44
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	44
Lessons and open questions in borderline resectable pancreatic cancer	43
Does filgotinib work for Crohn's disease?	43
The costs of inadequate toilet coverage in the Philippines	43
Standardising early liver transplantation for severe alcohol-related hepatitis	43
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	42
Gastroenterology training in Africa: an assessment of curriculum and perception	42
Cost of colorectal cancer care: sufficient to inform cancer policy?	41
World Hepatitis Day 2025: elimination at a critical juncture	41
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	40
Watch and wait for rectal cancer: towards data-informed surveillance	40
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	40
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	40
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	40
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	39
Spleen stiffness in portal hypertension algorithms: the next advance	39
Diet or optimised medical therapy for people with irritable bowel syndrome	39
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	38
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	38
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	37
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	36
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	35
Research in Brief	34
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	34

Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	34
6th World Congress of Paediatric Gastroenterology, Hepatology and Nutrition	34
Combination locoregional and systemic therapies in hepatocellular carcinoma	34
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	34
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	34
Hepatitis C virus in sub-Saharan Africa: a long road to elimination	34
Research in Brief	33
A coordinated multipronged attack: integrated care is the future for gastroenterology	33
Inequities in alcohol-related harm in the Philippines	32
Correction to Lancet Gastroenterol Hepatol 2021; 6: 784–92	32
The International Liver Congress 2022	32
Oncological safety of laparoscopic surgery for low rectal cancer	32
Polypoid lesions in the stomach and the colon: Cronkhite-Canada syndrome	32
Research in Brief	32
More is not always better for novel hepatitis B therapies	32
Accelerating point-of-care HCV viral load testing	32
Inclusion of patients with isolated ulcerative proctitis in clinical trials	31
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	31
The lottery of primary care for liver disease	31
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy	30
Endoscopic interventions for stricturing Crohn's disease	30
Time for a treat all approach for hepatitis B	30
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	29
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	28
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	28
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	28
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	27
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	27
Launch of the International Living Donor Liver Transplantation Outcomes Registry	27
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	27
Research in Brief	26
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	26
The Liver Meeting 2023	26
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	26
No accident: the UK infected blood scandal	25
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply	25
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	25
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	25
17th Congress of ECCO	25
Vedolizumab in paediatric IBD: a huge step forward but not there yet	24
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	24
Challenging stigma around alcohol misuse	24
Séverine Vermeire: advancing patient-centred research in IBD	23
Chronic Boom	23
A new chapter in the campaign to eliminate viral hepatitis?	23
Gastric examination by guided capsule endoscopy: a new era	23
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	22
Oral faecal microbiota transplantation in ulcerative colitis	22
Psychological therapies in inflammatory bowel disease	22
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	22
Haematopoietic stem-cell transplantation in Crohn's disease	22
Terlipressin for hepatorenal syndrome: opportunities and challenges	22
Tackling obesity: drugs are only part of the solution	22
Lessons from a trial of colesevelam for bile acid diarrhoea	22
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	21
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	21
Retina and liver fibrosis screening for patients with type 2 diabetes	21
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	20
A call for advocacy and patient voice to eliminate hepatitis B virus infection	20
Comparison of trends in early-onset colorectal cancer in North America and Europe	20
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	20
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	20
The urgent need to end hepatitis B stigma and discrimination	20
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	19
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	19
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	19
Local ablation in pancreatic cancer: some answers and more questions	19
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	19
Robotic pancreatoduodenectomy: preparing for the future	19
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	19
Are all post-ESWL pancreatitis events clinically significant?	18
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	18
Research in Brief	18
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	18
Financing viral hepatitis: catalysing action for impact	17
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	17
Diet or optimised medical therapy for people with irritable bowel syndrome	17
Research in Brief	17
Pooling samples for hepatitis C RNA detection	17
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	17
Variceal embolisation plus TIPS for variceal bleeding	17
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	16
Non-coeliac gluten sensitivity: from Salerno to Rome	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	16
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	16
An important step towards the long-term treatment of eosinophilic oesophagitis	16
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	16
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	15
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	15
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	14
Septic arthritis: a presentation of Crohn's disease	14
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	14
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	14
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	14